Review
Post-kala-azar dermal leishmaniasis
Post-kala-azar dermal leishmaniasis
E E Zijlstra, A M Musa, E A G Khalil, I M El Hassan, and A M El-Hassan
Post-kala-azar dermal leishmaniasis (PKDL) is a
complication of visceral leishmaniasis (VL); it is
characterised by a macular, maculopapular, and nodular
rash in a patient who has recovered from VL and who is
otherwise well. The rash usually starts around the mouth
from where it spreads to other parts of the body depending
on severity. It is mainly seen in Sudan and India where it
follows treated VL in 50% and 5–10% of cases, respectively.
Thus, it is largely restricted to areas where Leishmania
donovani is the causative parasite. The interval at which
PKDL follows VL is 0–6 months in Sudan and 2–3 years in
India. PKDL probably has an important role in interepidemic
periods of VL, acting as a reservoir for parasites. There is
increasing evidence that the pathogenesis is largely
immunologically mediated; high concentrations of
interleukin 10 in the peripheral blood of VL patients predict
the development of PKDL. During VL, interferon ␥ is not
produced by peripheral blood mononuclear cells (PBMC).
After treatment of VL, PBMC start producing interferon ␥,
which coincides with the appearance of PKDL lesions due to
interferon-␥-producing cells causing skin inflammation as a
reaction to persisting parasites in the skin. Diagnosis is
mainly clinical, but parasites can be seen by microscopy in
smears with limited sensitivity. PCR and monoclonal
antibodies may detect parasites in more than 80% of cases.
Serological tests and the leishmanin skin test are of limited
value. Treatment is always needed in Indian PKDL; in Sudan
most cases will self cure but severe and chronic cases are
treated. Sodium stibogluconate is given at 20 mg/kg for 2
months in Sudan and for 4 months in India. Liposomal
amphotericine B seems effective; newer compounds such
as miltefosine that can be administered orally or topically are
of major potential interest. Although research has brought
many new insights in pathogenesis and management of
PKDL, several issues in particular in relation to control
remain unsolved and deserve urgent attention.
Figure 1. PKDL papular lesions.
and transmission may be anthroponotic as well as zoonotic,
with rodents and canines as candidate reservoirs. Other VL
endemic areas include countries in the Mediterranean basin,
where Leishmania infantum is the species involved, and the
New World, where the identical Leishmania chagasi circulates;
in both areas canines are the reservoir hosts. Key features in
the clinical presentation of VL are prolonged fever,
hepatosplenomegaly, and weight loss. Dependent on the
geographical region, in L donovani endemic areas between 5%
and 60% of patients develop a dermatosis called post-kalaazar dermal leishmaniasis (PKDL) during or after treatment.
This skin condition has a tendency to become chronic and is
characterised by macular, papular, or nodular lesions in
which leishmania parasites may be seen. PKDL is therefore
considered a reservoir for leishmania parasites, especially
during interepidemic periods of VL. Although the condition
has been described for about 80 years, only recently has its
relevance, in particular in Africa, been fully recognised.
Recent studies have provided new insights into the
pathogenesis of this condition that has important clinical and
epidemiological implications.
Lancet Infect Dis 2003; 3: 87–98
Clinical features
Post-kala-azar dermal leishmaniasis (PKDL) is a
complication of visceral leishmaniasis (VL). VL, also known
as kala-azar, is caused by species of Leishmania that are
transmitted by the bite of a female sandfly, and it is estimated
that 200 million people are at risk for the yearly 500 000 cases.1
Most cases occur on the Indian subcontinent (India, Nepal,
Bangladesh) and east Africa (Sudan, Ethiopia, Kenya), where
Leishmania donovani is the causative parasite. Whereas VL is
considered to be anthroponotic in India with people as the
only known reservoir, in other areas the picture is less clear
THE LANCET Infectious Diseases Vol 3 February 2003
The clinical features have been best described in reports
from Sudan and India and are summarised in table 1.
EEZ is at the Department of Medicine, College of Medicine, Malawi;
AMM, EAGK, and AMEH are at the Department of Immunology and
Clinical Pathology, and IMEH is at the Department of Parasitology and
Medical Entomology, Institute of Endemic Diseases, Khartoum, Sudan.
Correspondence: Dr EE Zijlstra, Department of Medicine, College of
Medicine, Private Bag 360, Chichiri, Blantyre 3, Malawi.
Tel +265 1 670202 or +265 8 844318;
fax +265 1 673933 or 674700; email eezijlstra@malawi.net
http://infection.thelancet.com
87
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
Table 1. Comparison of most important features of Sudanese and Indian PKDL
Clinical
PKDL may occur in absence of previous VL
PKDL may occur while still on treatment for VL
PKDL may occur with evidence of visceralized disease (VL)
Most commonly described predilection over body
Type of rash
Lymphadenopathy
More severe disease found in
Concomitant other post-kala-azar manifestations
Sudan
India
Yes
Yes
Yes
Face>trunk>arms>legs
PN>MP>microP>M*
Frequent
Young children, short interval after VL
Yes
Yes
No
Yes
Face>trunk>arms>legs
Erythema, induration M,P,N
Rare
Not known
Yes
Epidemiology
Frequency of PKDL following VL
Highest prevalence reported in field study
Interval between VL and PKDL
most common
range
Age distribution
50–60%
4·8/100
5–10%
4·8/1000
0–6 months
0–13 months†
Children, mean age 6 years
2–3 years
6 months–32 years
Young adults
Diagnosis
Parasites may be demonstrated in smears
Parasites may be demonstrated by PCR
LST positive
Most difficult differential diagnosis
20–30%
83%
16–65%
Leprosy
20–40%
94%
0–67%
Leprosy
Treatment
Treatment with stibogluconate
Spontaneous cure
2–3 months
The rule
4 months
Not reported, all cases are treated
*PN=papulo-nodular, MP=maculo-papular, MicroP=micropapular, M=macular, N=nodular. †In neighbouring Kenya, an interval of 30 years has been reported.
Type of rash
Distribution
The rash has been best described from Sudan and India. In
a recent cross-sectional descriptive study of 105 patients
with PKDL in eastern Sudan, a papular or nodular rash was
most frequently seen (51%) (figures 1 and 2); other types
of rash were maculopapular (23%), micropapular
(measles-like) (17%) (figure 3) and macular (9%)
(figure 4).2 In a longitudinal study in the same area in
which VL patients were monitored after treatment, the rash
was almost always a mixture of a measles-like and
maculopapular eruption.3
From India, three main presentations have been
described, of which one or two may predominate:
erythema and induration on the butterfly area of the
face that shows photosensitivity; multiple symmetrical
hypopigmented macules that may coalesce; and
combinations of papules, nodules, and plaques.4–6 Other
unusual manifestations include the annular, warty,
papillomatous, fibroid, or xanthomatous types. From
China and Nepal the same hypopigmented macular,
maculopapular, and nodular types of rash or combinations
have been described.7,8
Although there are differences in description of clinical
findings from Sudan and other areas, in most reports
macular (maculo) papular and nodular lesions are
described as the hallmarks of PKDL, and are differentiated
arbitrarily by size. Nodular lesions probably develop from
papules over time, which seems also to be the case in PKDL
reported from HIV-endemic areas. The erythema in the
butterfly area is probably not appreciated in the darker
African skin. Ulceration is not a feature of Indian or
Sudanese PKDL.
In Sudanese patients PKDL lesions typically appear
around the mouth and spread to other parts of the face
(figure 5); subsequent spread to upper arms and chest
may follow. This pattern is most consistent in papular and
nodular PKDL, but to a lesser extent in macular lesions
as they may be more widely spread over the body. After
treatment or during spontaneous regression, the lesions
around the mouth remain longest and are the first to
recur in case of relapse.9 In most severe cases the whole
body may be affected sometimes with mucosal lesions
on the lips or palate.9 Exposure to ultraviolet light
may be an important factor in its pathogenesis and
initially the distribution of the rash may mirror clothing
habits.3
In some patients, the PKDL lesions occur preferentially
in scars that become more prominent and regress
again after treatment of PKDL (Köbner phenomenon).2
The typical pattern of distribution has resulted in the
description of three clinical grades of severity. In
grade one a scattered maculopapular or nodular rash
occurs mainly in the face with or without some lesions
on the upper chest and arms. Grade two is defined
as a dense maculopapular or nodular rash covering most of
the face and extending to the chest, back, upper arms,
and legs, gradually becoming less distally, with only
scattered lesions on the forearms and legs. Grade
three is defined as a maculopapular or nodular rash
covering most parts of the body, including hands
and feet. In grade three crusting, ulceration, sloughing,
scaling, and spreading to the mucosa of the lip
(cheilitis) and the palate may occur (figure 6).2
88
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
Figure 4. PKDL macular lesions.
Other clinical findings
Figure 2. PKDL nodular lesions that are confluent with plaque formation.
The distribution and sequence of spread from the face to
other parts of the body has not been described in Indian
PKDL in longitudinal studies. However, especially for
nodular lesions, similar predilection of the face with less
frequent involvement of the arms and trunk further
decreasing distally suggests a similar distribution pattern.5,10
As in Sudan, macular lesions do not seem to involve the
face as frequently and may be more prominent on the trunk
and limbs. In some reports it has also been suggested that the
macular patches and the erythema precede the appearance of
nodules; the influence of ultraviolet light has also been
suggested.4,5,6
Patients are generally well and do not have fever.11 In the
endemic area in eastern Sudan, where people are very much
aware of the disease, which they call “kala-azar”, and where
many have lost children because of this disease, the
occurrence of a PKDL rash after treatment is regarded as a
favourable sign (“the disease has come out”) meaning that the
child is going to survive (EE Zijlstra and AM El Hassan,
personal observation). In patients who develop PKDL early
after VL there is a gradual transition from VL—during which
the patient is ill, but without a skin rash, with demonstrable
parasites in lymph node, bone marrow, or spleen—to
PKDL—where the patient is well, the rash has developed, and
parasites are no longer demonstrable except in the skin. Some
patients present in the intermediate stage; one study showed
that 15% of 416 PKDL patients had evidence of disseminated
disease as shown by parasites in lymph node or bone-marrow
aspirates. These patients with PKDL and concomitant VL may
be more appropriately referred to as para-kala-azar dermal
leishmaniasis cases and they take an intermediate position
between VL and PKDL; they have larger spleen size (mean 4·1
cm [SD 3·6]) compared with PKDL patients who did not have
demonstrable parasites in the bone marrow and lymph nodes
(mean 2·8 cm [3·2]) but smaller than VL
patients (mean 9·9 cm [5·4]).2 At least seven patients with
similar concomitant VL and PKDL have been
reported from India;12 another five patients with VL and
presumably PKDL were seen in Iran,13 and one patient
in France.14 Figure 7 shows the hypothetical association
between the decreasing parasite load, the emerging
immunological response, and the ensuing change in clinical
syndrome.
Lymphadenopathy may be seen in Sudanese VL and
PKDL but it is rare in Indian VL and PKDL.15
Associated conditions
Figure 3. PKDL micropapular lesions (measles-like).
THE LANCET Infectious Diseases Vol 3 February 2003
PKDL may coexist with VL (see above); in Sudan, other
post-kala-azar manifestations such as post-kala-azar
mucosal leishmaniasis, uveitis, coniunctivitis, and
blepharitis may be seen simultaneously in the same
patient.16–18 Other complications after VL include post-kalaazar laryngitis and colitis.19 Similarly, in studies from India,
http://infection.thelancet.com
89
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
Age and sex distribution
The age distribution of PKDL follows that of VL; in Sudan,
the mean age of patients with PKDL and VL was identical (6
years) with equal numbers among boys and girls. Younger
children have more severe PKDL;2,3,11 in India and Nepal,
most cases are young adults with male predominance
(1·3–3/1).4,8,23
There are, however, discrepancies between hospitalbased and community-based studies in India suggesting
under-reporting of PKDL cases in children (age group 0–9
years) and females.23
Interval between VL and PKDL
Figure 5. PKDL patient with typical perioral lesions.
involvement of the mucosal surfaces, in particular in the
mouth and the larynx, as well as eye involvement such as
keratitis has also been described.4,20
Place of PKDL in the spectrum of manifestations
of L donovani.
Figure 8 shows the inter-relationship between PKDL and
other clinical manifestations of leishmania infection in
Sudan. PKDL may occur without a previous history of VL,
or may come after or concomitant with a leishmanioma
(figure 9). After PKDL subsides, immunity is the rule; in rare
instances a patient with PKDL may have a relapse of VL.21
One study from India estimated this to occur in one of
every 700 patients with PKDL. Reinfection, reinvasion from
the skin, and renewed multiplication of latent parasites
from the viscera have been suggested.21 A degree of
immunosuppression induced by intercurrent diseases such
as measles, malaria, and tuberculosis has been suggested by
Nandy et al, 199822 as an explanation for relapse of VL in
PKDL patients.
In east Africa (Sudan, Kenya) the interval between VL and
PKDL is short; all cases present 0–13 months after treatment
of VL with most presenting within the first 6 months.2,11,24
Longer intervals of 3–30 years have also been reported.25 8%
of cases have no previous history of VL;9 others present with
concomitant VL and PKDL or may develop PKDL while still
on VL treatment (up to 18%).2
A different situation exists in Asia (India, Nepal), where
PKDL follows VL with an interval of 6 months to 6 years and
most patients present after 2–3 years.4,10 In 15–20% of cases
there is no previous history of VL.4 Longer intervals of up to
32 years have been reported.26
Epidemiology
PKDL occurs mainly in L donovani-endemic areas and most
studies reported are from Asia (mainly India) and east
Africa, mainly Kenya and Sudan (table 1).
Asia
In India, PKDL follows VL in 5–10% of cases.4 The first cases
of PKDL were reported from India by Brachmachari27 in
1922, who described the occurrence of eruptions and
plaques in the skin containing leishmania parasites in
patients previously treated for VL.
After decades of intense transmission
in India, mainly in Bihar, the
incidence of both VL and PKDL
declined in the early 1960s, probably
the result of residual DDT spraying in
the National Malaria Eradication
Programme, which affected sandflies
as well as malaria mosquitos. After
discontinuation
of
insecticide
treatment, a severe epidemic of VL
occurred in Bihar and west-Bengal.28,29
In the interepidemic period, the
number of PKDL cases outnumbered
the VL cases, suggesting that the
PKDL patients may have served as a
reservoir. 10,28 Entomological work
showed that Phlebotomus argentipes,
the proposed vectors of VL in India,
become infected and develop
promastigotes in their midgut when
allowed to feed on PKDL patients29,30
Figure 6. The distribution of PKDL may be described in grades of severity (see text for further
explanation).
and, therefore, seem capable of
90
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
transmitting leishmania. This finding is in agreement with
earlier reports that suggest that transmission of VL is
anthroponotic in this area and no other vertebrate host than
people has been found.31 The importance of PKDL in the
epidemiology of leishmaniasis in India was also shown by
Dye and Wolpert,32 who showed that the presence of as few
as 0·5% durably infectious (PKDL) patients during an
epidemic may cause VL to become endemic. Although there
are few studies on the epidemiology of PKDL in India, one
study reported a prevalence rate of 4·8/1000 in two villages
in Varanasi district.33 Other countries in the Indian
subcontinent from where PKDL has been reported include
Bangladesh and Nepal; both are within the same
nosogeographical area of L donovani.8,34
In China, VL occurs in the anthroponotic form
(probably caused by L donovani) in the eastern plains for
which effective control measures have been implemented;
after 1960 only sporadic cases of VL and PKDL have been
reported from that area.35–37 There are no reports on PKDL
from the zoo-anthroponotic form of VL that occurs in
central and north-west China, from where L infantum has
been isolated from patients and dogs.35 From Taiwan both
imported cases from mainland China and autochtonous
patients have been reported.38,39
East Africa
In Sudan, reports on PKDL remained scanty after the first
report in 1938 by Kirk and Drew.40 Kirk and Sati41 described
cutaneous infection in 57·5% of VL cases, but no clear
distinction was made between PKDL and leishmaniomas.
Sporadic cases were reported from two hospital-based
studies.42,43 Similar to what was suggested from India, PKDL
cases may have served as a reservoir for parasites at times
when numbers of VL cases are low.44
In the 1990s a severe VL outbreak occurred in the
endemic area in eastern Sudan with incidence rates in one
village of 20·4–38·4/1000 person-years.45 56% of VL cases
developed PKDL with similar age and sex distribution as
VL cases.9,45 Between 1991 and 1996 416 patients with PKDL
were seen in a cluster of villages in the same area.2 As in
most patients, the skin lesions will persist for months and in
some for years and a considerable number of people in any
village can be expected to have PKDL. Indeed, in another
study the point prevalence of PKDL in one village in the
Parasites
Immunity
VL
PKDL
PKDL/VL
Treatment
Figure 7. The hypothetical relationship between decreasing parasite load,
increasing immunity, and ensuing clinical presentation during treatment of
visceral leishmaniasis.
THE LANCET Infectious Diseases Vol 3 February 2003
Subclinical
infection
Death
Infection
VL
Relapse
Cure/
immunity
PKDL
Leishmanioma
Figure 8. Diagram showing the interrelationship of clinical manifestations
that may follow after leishmania infection in Sudan; the thickness of the
lines corresponds with the likelihood of the occurrence of the following
event. With permission from: Eldryd Parry, Richard Godfrey, Geoffrey Gill,
David Mabey, eds. Principles of Medicine in Africa. Cambridge:
Cambridge University Press; in press.
area was 4·8%.46 A recent study on the natural history of
PKDL in the same endemic area showed that the mean
duration of PKDL was 9·7 months (range 2–28 months)
before clearing.3 It seems likely that PKDL could have a role
in transmission in Sudan, but so far this has not been
proved; it is not clear whether transmission of VL in Sudan
is anthroponotic or zoonotic, or both. L donovani has been
shown by culture and PCR in materials from patients with
VL, PKDL, and from rats and dogs; cultures that were
further analysed by enzyme electrophoresis showed that all
zymodemes of L donovani found in PKDL patients have
also been seen in patients with VL and in dogs.47,48
In Ethiopia, where the endemic area of eastern Sudan
extends into the Metema-Humera focus, a recent study
showed a PKDL rate of 14% in patients who were seen only
once at 6 months after treatment. By contrast with the
Sudanese focus HIV infection is spreading in this area.
PKDL was more common in HIV-positive patients (27·3%
and 13·3% in HIV-positive and HIV-negative patients,
respectively).49
In Kenya, PKDL was first described by Manson-Bahr50
in 1959. Reported PKDL rates after VL show considerable
variability in four studies of 0·05%,51 1%50, 6%,24 and 30%.52
From L infantum-endemic areas reports on PKDL are
scarce. Along the Mediterranean basin, sporadic cases
occurred in Spain, Italy, France, and Israel; cases have also
been reported from Iran.53–65 In one study in Spain up to 15%
of patients developed cutaneous lesions after VL, which
could be referred to as PKDL.54 In another report a patient
had a PKDL rash for 15 years caused by a not previously
described zymodeme of L infantum (MON-253) without
obvious immunosuppression or HIV infection.61 More
recent reports are from HIV-VL coinfected patients, in
whom the clinical presentation of VL can be unusual and
cutaneous lesions have been described to precede,
accompany, and follow VL after treatment. A case of a
dermatofibroma parasitised by leishmania parasites has been
described; another patient developed Kaposi’s sarcoma-like
lesions in the course of treatment of a third relapse of VL. It
is unclear whether these are non-typical forms of PKDL or
parasitised skin lesions in the course of VL.62,64
http://infection.thelancet.com
91
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
experiments.22 Other studies suggest that different strains are
involved in VL and PKDL; differences in antibody responses
with variable patterns of reactivity by VL and PKDL serum
samples have been shown.78 One study showed the cloning
of a kinetoplast DNA mini-fragment from leishmania
strains that was specific for strains from PKDL patients but
not for strains from VL.79 Bozza et al80 provided support for
this and showed that a strain from a PKDL patient had close
relationship with L tropica and not with L donovani or
L infantum.
Pathogenesis and immunology
Figure 9. PKDL in combination with leishmanioma. The girl did not have a
history of VL.
One HIV-infected patient from Italy developed
PKDL after successful treatment of VL followed by highly
active antiretroviral therapy (HAART); L infantum
was identified in the skin by PCR58 A similar patient was
described from Israel.59 PKDL has also been reported in
patients with other forms of immunosuppression—eg,
kidney transplant recipients or patients with Hodgkin’s
lymphoma.14,57,65 In South America, where VL is mainly
caused by L chagasi, PKDL seems uncommon; in one
HIV-infected patient with VL caused by disseminated
Leishmania braziliensis (a parasite that normally is
restricted to the skin or mucous membranes) cutaneous
lesions developed while relapsing from a previous episode
of VL.66 In another case PKDL developed after VL caused
by Leishmania amazonensis.67
Parasites
Several studies from Sudan showed that in cultures from
bone marrow or lymph node aspirates from patients with VL
analysed by isoenzyme electrophoresis, L donovani,
L infantum, and Leishmania archibaldi, which takes an
intermediate position in the cladogram, are seen.68–70
However, the three species were all seen to be L donovani
sensulato by Southern blotting and fingerprinting and were
clearly different from a L infantum reference strain,69 which
supports association between VL and PKDL in this area with
L donovani rather than with L infantum.
Of the three species, seven zymodemes have been seen to
be circulating in the VL endemic area in eastern Sudan. Four
zymodemes have now been isolated from PKDL patients:
(MON-18 L donovani; MON-30 and MON-267 L infantum;
and MON-82 L archibaldi),71 which does not suggest an
association between a particular parasite subspecies and risk
of developing PKDL. Similarly, although polymorphism was
shown among L donovani strains using PCR single-strand
conformation polymorphism, no correlation was found with
the clinical manifestations of VL and PKDL.72
In India, Bangladesh, and Nepal strains that were
isolated from VL and PKDL patients were all typed by
electrophoresis as zymodeme LON-41 or MON-2;73–76 earlier
typing found serologic similarity between strains,77 and the
strains isolated from PKDL could cause VL in animal
92
The exact mechanisms underlying the development of
PKDL still remain to be elucidated. There is accumulating
evidence, however, that (developing) immune responses
have a major role.
In VL a specific cell-mediated immune (CMI) response
to the leishmania parasite is absent, and only develops after
treatment. This can be measured in vitro in experiments in
which peripheral blood mononuclear cells (PBMC) are
stimulated or in vivo by the leishmanin skin test.
Early studies from India showed CMI responses during
VL while two-thirds of patients with PKDL had a positive
response after stimulation of PBMC, with a more marked
CMI response in newly acquired PKDL (duration a few
months to 1 year) compared with chronic PKDL (duration
8–30 years).81 In another study, all ten PKDL patients
showed absent specific CMI response before treatment with
intact response to (phytohaemagglutinin) mitogen, whereas
in VL patients CMI responses both specific and generalised
were absent. After treatment with antimony, specific CMI
responses were restored in both VL and PKDL patients but
this response was slower and took a larger amount of drugs
in PKDL.82
More recent studies showed that during VL the immune
response of PBMC to leishmania antigens is absent or
skewed towards a Th2-type of response.83 After treatment
the response changes from a Th2 to Th1 or a mixed
Th1/Th2 type.83 The PBMCs of all Sudanese PKDL patients
proliferate in response to leishmania antigen and produce
interferon ␥; in about 20% of patients the cells also produced
interleukin 10.84
In a further longitudinal study in Sudan, Gasim et al85
monitored 29 VL patients for 6–24 months from the time of
diagnosis to the time of cure or development of PKDL. In
both groups parasites were detected in the skin during VL,
PBMC did not show proliferation to leishmania antigen, and
interferon-␥ production was absent. Patients with VL who
went on to develop PKDL had higher interleukin 10
concentrations in the skin and peripheral blood than those
who did not develop PKDL. At follow-up, both groups did
not differ in the acquisition of a degree of immunity as
evidenced by proliferation of PBMC to leishmanial antigen
as well as production of interferon ␥ and interleukin 10.
However, it was noted that at day 30 after VL treatment,
those who developed PKDL had higher PBMC
immunological responses compared with those who
developed PKDL later, suggesting that there is an association
between the occurrence of the PKDL rash and the
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
appearance of leishmania-specific lymphocyte reactivity.
The development of PKDL apparently depends on capacity
to mount an immune response since in patients co-infected
with HIV and VL, PKDL may develop after the start of
HAART suggesting that PKDL develops in the context of
immune reconstitution. This finding was also supported by
an increased CD4 count, restored interferon-␥ production,
and decreased interleukin-10 concentrations during PKDL
compared with measurements during the VL episode.58,59
There
seem
to
be
discrepancies
in
the
immunohistopathological findings in PKDL lesions from
Indian and Sudanese patients. In the early stages of Indian
PKDL limited numbers of CD4+ and CD8+ lymphocytes
were seen in hypopigmented lesions; as the disease
progresses to the nodular type, in dermal lesions as well as in
lymph nodes a preponderance of CD8+ cells was found.86 By
contrast in all lesions of Sudanese patients with PKDL most
cells were CD3+ T cells with preponderance of CD4+ over
CD8+ cells.84 Macrophages were seen in variable numbers.
Natural killer cells were scarce. Interleukin 10 was the most
prominent cytokine in the lesions. However, interferon ␥
was seen in all and interleukin 4 in most lesions. It was
suggested that balance of the cytokines in the lesions may
determine the outcome of the disease.
The leishmanin skin test (LST) measures delayed type
hypersensitivity in the skin by injection of killed leishmania
amastigotes intradermally into the forearm. After 48–72 h
the induration is measured in mm; a reaction 5 mm or more
is usually considered positive. The LST is typically negative
in VL and positive in 80% of successfully treated patients
after 6 months.87 PKDL patients take an intermediate
position: those with PKDL and concomitant VL are LST
positive in 11% and those without concomitant VL in 37%.2
Pathology
Irrespective of the clinical forms the epidermis shows several
changes in different combinations. These include
hyperkeratosis, parakeratosis, focal acanthosis, or atrophy of
the rete pegs, and liquifaction degeneration of the basal cells.88
The last is associated with focal infiltration of the basal layer
by lymphocytes. Under electron microscopy the lymphocytes
are in intimate contact with melanocytes and basal
keratinocytes. The latter cells seem to be damaged by the
infiltrating lymphocytes, which is the major cause for the
depigmentation seen clinically. The dermis is infiltrated by a
mixture of lymphocytes and macrophages. By contrast with
lesions of cutaneous leishmaniasis caused by Leishmania
major (oriental sore) plasma cells are virtually absent in PKDL
lesions. Lymphocytes are the dominant cells in most biopsies.
In about half the cases epithelioid cells, scattered individually
or forming compact granulomas, are seen. Compact
granulomas are seen more frequently in nodular than macular
and papular lesions.88 A neuritis involving small cutaneous
nerves in PKDL lesions has been shown that may cause
confusion in the differentiation from leprosy.89
The reported presence of parasites in biopsies varies,
probably because of differences in type of rash and duration
of lesions. In one Sudanese study all 15 biopsies showed
parasites.11 In another comparative study, parasites could be
THE LANCET Infectious Diseases Vol 3 February 2003
seen in only 17% of haematoxylin and eosin-stained
sections; using a monoclonal antibody specific for
L donovani leishmania parasites improved sensitivity to 88%
of the biopsies.90 In India parasites are reported to be seen in
about 90% of biopsies.91,92 Parasites are more easily shown in
nodules than in papules and macular lesions.
Predictors of PKDL
No convincing clinical predictors have been identified that
are helpful to predict who will develop PKDL and who will
not. One Sudanese study showed spleen size at time of VL
to be correlated with development of PKDL,85 but another
study did not confirm this.2 In a further study from Sudan
it was suggested that inadequate treatment regimens may
be important.2 This possibility was also suggested from
India where all patients presenting with PKDL had
short duration of treatment for VL.3 It is unclear whether
more effective treatment of VL—eg, with liposomal
amphotericin would prevent PKDL; one limited
comparative study in Sudan between stibogluconate and
liposomal amphotericin B (AmBisome) in the treatment of
VL, showed less PKDL in the amphotericin B group than
the stibogluconate group.93
Several studies on Sudanese patients examined factors
relating to the parasite and various immune responses.2,3,85,94,95
Persistence of parasites after successful treatment of VL may
play a part. Osman et al94 showed that leishmanial parasite
DNA was present by PCR in microscopically negative
inguinal lymph nodes taken after treatment of VL in 82% of
cases. Interestingly, 36% of these developed PKDL and 23%
developed relapse of VL, whereas none of the 18% who were
PCR negative developed these complications. Gasim et al95
showed that patients who had high C-reactive protein levels
(>40 µg/mL) at the time of VL had higher risk of developing
PKDL compared with those with C-reactive protein below
30 µg/mL. In another study high concentrations of
interleukin 10 in the blood, and the presence of this cytokine
in normal-looking skin during VL, predicted the subsequent
development of PKDL.85
PKDL is more severe at a younger age and the conversion
rates in the LST are lower in more severe PKDL. This may be
the result of generalised ultraviolet light exposure since very
young children often walk about undressed; it may also
indicate the immaturity of the immune system in the very
young.2,3
Another factor associated with the severity of PKDL is
the interval between end of VL treatment and occurrence of
PKDL; significantly more severe PKDL occurs after a shorter
interval, suggesting a continuing Th2 response.3
Diagnosis
In most endemic areas diagnosis will be made clinically by a
history of previous VL, the temporal association with VL, the
distribution and appearance of the lesions, by ruling out
other disorders, and by the response to treatment.
Parasitological confirmation may be sought if in doubt.
Studies from India showed that smears are more likely to
show amastigotes if taken from a larger lesion or from
nodular (67–100%) lesions compared with papular
http://infection.thelancet.com
93
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
Table 2. Overview of studies on treatment of PKDL; only studies with more than one patient are included unless no other
data on a particular drug are available.
Reference Year
Country Type of
study
Drug
Daily dose
Yesudian113
1974
India
Case series Amphotericin B Max 25 mg
Variable
alternate days
2
1 cured after 717·5 mg in 3 months;
1 cured after 375 mg in 6 weeks
Thakur28
1984
India
Case series SSG or SAG
10 mg/kg adult 20 days
20 mg/kg child 20 days
20
7 (36%) cured; 13 (64%) relapsed
Saha114
1985
India
Case study
600 mg bd
2 courses
of 15 days
1
1 cured
Thakur115
1987
India
Randomised SSG
study
10 mg/kg
15 mg/kg
20 mg/kg
120 days
120 days
120 days
36
36
36
18 cured
24 cured
33 cured
Rai33
1989
India
Case series SAG
10 mg/kg
40 days
13
13 cured
Thakur10
1990
India
Case series SSG
20 mg/kg*
120 days
53
47 (88%) cured after 120 days
2 cured after 180 days
2 cured after 200 days†
Muigai24
1991
Kenya
Case series SSG
Nil
20 mg/kg
30 days
7
5
6 cured, 1 relapsed, cured after SSG+allopurinol
5 self cured
Ramesh116
1992
India
Case series Ketoconazole
800 mg
Variable
4
1 cured after treatment for 9 months;
2 stopped because of side-effects; 1 defaulted
El-Hassan11
1992
Sudan
Case series SSG
20 mg/kg
10 mg/kg
10 mg/kg
30 days
15 days
30 days
8
7
2
4 cured, 4 relapsed
2 cured, 5 improved with residual lesions
2 not improved
Ramesh91
1993
India
Case series SAG
20 mg/kg‡
105-150 days 14
9 cured after 120–130 days
3 cured after 105 days
2 cured after 150 days
Khalil117
1996
Sudan
Case series Terbinafine
+ itraconazole
250 mg
200 mg
4 weeks
4 weeks
9
1 cured after 2 weeks extension
8 initially improved but relapsed later
Ramesh118
1996
India
Case series Allopurinol
20 mg/kg
variable
3
2 cured after 20 and 24 months;
1 improved but stopped after 6 months
(side-effects)
Hashim119
1995
Sudan
Case series Liposomal
2
2 cured
11
11 cured
11
7 cured
Rifampin
Ketoconazole
Duration
Number Outcome
studied
amphotericin B
Thakur120
1997
India
Comparative Amphotericin B 1 mg/kg
study
SAG
20 mg/kg*
3x20 days§
6–10 x
20 days§
Garg8
2001
Nepal
Case series SAG
20 mg/kg
30–72 days
21
21 cured
*Maximum daily dose 850 mg. †Not mentioned for two patients. ‡Maximum daily dose 1g. §Courses of 20 days with 20 days drug free interval. SSG=sodium stibogluconate.
SAG=sodium antimony gluconate.
(36–69%) and macular lesions (7–33%).4,96 Cultures may
give higher yield than smears but are likely to be
contaminated. Monoclonal antibodies and PCR increase the
diagnostic yield considerably to 88% and 83–94%,
respectively, but these techniques are restricted to well
equipped laboratories.90,97–99
Serological tests such as the direct agglutination test
(DAT) and ELISA are of limited value in endemic areas and
so far no specific and practical serological test exists for
PKDL since after VL leishmanial antibodies may persist for
years and a positive antibody test in a patient with
suspected PKDL may be the result of previous VL. Similar
titres in the DAT and rK39 IgG ELISA are reported in
Indian and Bangladesh PKDL compared with VL.100,101 In
Sudan the positivity rate in the rK39 strip test was equal
among patients cured of VL without PKDL and patients
with PKDL.102
94
Adaptations of the antigen used may be helpful. One
study showed antibody profiles to differ in VL and PKDL
since only 10% of PKDL patients showed an antibody
response to a 200 kDa axenic amastigote antigen compared
with 97% of patients with VL; in both conditions
antibodies to leishmania amastigote soluble antigen could
be shown.103 In another study from India, western blot
analysis also showed different humoral responses in serum
samples of PKDL patients compared with VL patients; two
antigens (110 and 65 kDa) elicited an antibody response in
97–100% of PKDL patients, compared with 51–71% of VL
patients and none of the control patients including patients
with leprosy.104 Given the often long interval between VL
and PKDL in India, it was argued that this immune
response was likely to be the result of the occurrence of
PKDL rather than persistence of antibody of VL. A
competitive ELISA using L donovani-specific monoclonal
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
antibody was positive in all seven Indian PKDL patients
tested and may prove useful to monitor the success of
treatment.105 Serological tests such as DAT and rK39 strip
test may help exclude other conditions, in particular
leprosy;101,104 a rK39 strip test detected 91% of PKDL cases
with 100% specificity in India.106
After VL, 80% of patients are expected to develop a
positive LST after 6 months. For PKDL patients in Sudan,
varying LST positivity rates of 16%, 32%, and 65% have
been reported which is probably a function of time after VL,
severity of PKDL, and antigen used.2,3,9 There is no difference
in conversion rates between those who develop PKDL and
those who do not.2 In India conversion rates vary between
0% and 67%.81,82,107
Both in Indian and Sudanese PKDL the differential
diagnosis includes a large number of other skin conditions of
which leprosy is not uncommonly mistaken for PKDL;
distinguishing between these two conditions may be
difficult.108–112 An overview of differential diagnoses has been
published.2
Treatment
There are few controlled studies on the management of
PKDL and most data come from small case series. In
addition, there are differences in approach according to
geographical area. An overview of studies available is given
in table 2.
Spontaneous healing
In Sudan, spontaneous healing frequently occurs; in one
study in non-severe PKDL this was found in all 134 patients,
of whom 84% healed within 1 year.3 Patients with grade-one
and mild grade-two PKDL may therefore be left untreated
under careful follow-up. Those who will develop persistent
lesions may be identified by significantly higher titres in the
DAT and a more often negative LST.3
therefore it is probably better used in lower dose as a second
drug in combination with SAG.116 In Sudan, a combination
of terbinafine and itraconazole was not effective.117 In India,
rifampicin was shown to be effective in one case report; in
another case series allopurinol cured two patients after
20–24 months, while a third patient improved but
developed side-effects after 6 months.114,118
Amphotericin B was shown to be effective with low
toxicity in antimony-unresponsive Indian VL patients and
seen to be superior to pentamidine.122 Experience with
amphotericin B in PKDL is limited;113,120 in one study in
India, amphotericin B appeared more effective (all 11
patients cured after 120 days) compared with SAG (seven of
11 cured after up to 400 days of up to ten courses of
treatment), although the result was not significant.
Amphotericin B is, however, more expensive and showed
some nephrotoxicity.113 Similarly, liposomal amphotericin B,
which is probably the most effective drug for VL, could be of
potential benefit in PKDL; however, so far this has been
reported effective in three case reports only.56,119 The new oral
compound miltefosine that has been shown effective in the
treatment of Indian VL is of considerable potential interest
for treatment of PKDL since patients who are otherwise
not ill may resent a repeated and lengthy course of
daily treatment with intramuscular or intravenous
stibogluconate.123 Topical application may be an alternative
because miltefosine has good skin penetration and is used as
topical treatment for skin metastasis of breast cancer; it has
been shown to be effective in experimental cutaneous
leishmaniasis.124,125
Unresolved issues and areas for research in PKDL
Pathogenesis and epidemiology
●
Conclusive identification of risk factors for PKDL
●
Differences between Leishmaniasis donovani and Leishmaniasis
infantum with regard to development of PKDL: involvement of certain
subspecies, immune responses after infection, parasite load, response
to treatment, genetic factors
●
Explanation of differences in interval between VL and PKDL between
African and Asian PKDL; need for longitudinal studies
●
Confirmation of PKDL as a reservoir in transmission of VL
●
Identification of treatment regimens and drugs (or combinations of
drugs) for VL to prevent development of PKDL
Treatment with pentavalent antimony
In Sudan, patients with severe PKDL, those with lesions
that have persisted for more than 12 months, and those
with concomitant anterior uveitis or mucosal lesions are
best treated from the start; treatment is with sodium
stibogluconate.3 No firm data are available on the optimal
treatment regimen; clinical experience has shown that since
20 mg/kg per day for 30 days was not satisfactory,
treatment may need to be prolonged to 2–3 months or
alternative treatment may be necessary.2,11
In India treatment is the rule and cure rates are 64–92%
with sodium antimony gluconate (SAG) 20 mg/kg per day
for 120 days.4,111,115
Other treatment
Especially in India, where resistance to SAG is a serious
problem, alternative treatment options have been explored.
There is one case of successful surgical removal of
a localised lesion by shave excision.121 Pentamidine has
been shown to be effective (cure rate 93%) but with
serious toxicity.28 Ketoconazole in high dose (800 mg/day)
has to be given for up to 9 months to achieve cure;
THE LANCET Infectious Diseases Vol 3 February 2003
Management
●
Firm clinical and/or laboratory markers of PKDL that predict rapid
self-cure or need for treatment
●
Identification of effective and non-toxic treatment regimens for PKDL
●
Evaluation of miltefosine as a potential candidate for treatment (oral or
topical administration)
●
Clinical and/or laboratory markers that predict parasitological cure after
treatment
Control
●
Use of bednets as a tool to prevent sandflies from feeding on PKDL
patients
●
Education and training of health workers to diagnose and manage
patients with PKDL in areas of high incidence
●
Integration of diagnosis and management of PKDL in control strategies
in VL endemic areas
http://infection.thelancet.com
95
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
Post-kala-azar dermal leishmaniasis
Search strategy and selection criteria
The data in this review were from papers identified from
PubMed searches using the terms, “post-kala-azar dermal
leishmaniasis”, “post-kala-azar”, “dermal leishmaniasis”,
“PKDL”, and “PKADL”. Additional data originated from papers
in reference lists of reviewed articles and from the authors’
personal archives. Reference were selected for their scientific
contribution to various aspects of PKDL. Case reports were
used for areas in which not other studies were available.
English and French papers were reviewed.
and repeated demonstration of leishmanial DNA may not
reflect the presence of live parasites. Parasitological cure
may well precede clinical cure leading to unnecessary long
treatment regimens with considerable toxicity. In addition,
clinical response may differ according to PKDL type;
nodules and papules disappear in 120 days, macules in 200
days.10 PKDL usually heals completely, but in longstanding
cases scarring may occur (figure 10).
Conclusion
Figure 10. This girl had PKDL for 3 years. After the first course of sodium
stibogluconate (top) some lesions are healing but with scar formation.
Multiple depressed scars after a second course of treatment (bottom).
Treatment studies in PKDL are hampered by the
absence of a clear and early marker of cure. Since parasites
may be scarce or absent in smears taken at diagnosis,
parasitological cure is difficult to assess in repeated skin
smears. Taking repeated biopsies is unattractive and
impractical. Similarly, molecular techniques are not helpful
References
1
2
3
4
5
6
7
8
9
96
Desjeux P. Leishmaniasis. Public health aspects and
control. Clin Dermatol 1996; 14: 417–23.
Zijlstra EE, Khalil EAG, Kager PA, El-Hassan AM.
Post-kala-azar dermal leishmaniasis in the Sudan:
clinical presentation and differential diagnosis. Br J
Derm 2000; 142: 136–43.
Musa AM, Khalil EAG, Raheem MA, et al. The
natural history of Sudanese post- kala-azar dermal
leishmaniasis: clinical, immunological and prognostic
features. Ann Trop Med Parasitol (in press).
Ramesh V, Mukherjee A. Post-kala-azar dermal
leishmaniasis. Int J Derm 1995; 34: 85–91.
Napier LE, Das Gupta CR. A clinical study of postkala-azar dermal leishmaniasis. Indian Med Gaz
1930; 65: 249–57.
Girgla HS, Marsden RA, Singh GM, Ryan TJ. Postkala-azar dermal leishmaniasis. Br J Derm 1977; 97:
307–11.
Leng Y. A review of kala-azar in China from 1949 to
1959. Trans R Soc Trop Med Hyg 1982; 76: 531–37.
Garg VK, Agrawal S, Rani S, et al. Post-kala-azar
dermal leishmaniasis in Nepal. Int J Derm 2001; 40:
179–84.
Zijlstra EE, El-Hassan AM, Ismael A. Endemic kalaazar in eastern Sudan. Post-kala-azar dermal
leishmaniasis. Am J Trop Med Hyg 1995; 52:
299–305.
PKDL is now recognised as a frequent complication of VL
in most endemic areas with important clinical and
epidemiological implications. Although in the past decade
studies have considerably increased our understanding
of PKDL, many issues remain unresolved and should
be the subject of further research (panel). These might
include studies that increase our basic understanding in
pathogenesis and management, but should also be focused
on the public-health aspects of PKDL, especially in relation
to developing control strategies in VL endemic areas.
Acknowledgments
This project was supported in part by UNDP/World Bank/WHO Spcial
Program for Research and Training in Tropical Diseases (project
#980947).
Conflict of interest
None declared.
10 Thakur CP, Kumar K. Efficacy of prolonged
therapy with stibogluconate in post kala-azar
dermal leishmaniasis. Indian J Med Res 1990; 91:
144–48.
11 El-Hassan AM, Ghalib HW, Zijlstra EE, et al. Post
kala-azar dermal leishmaniasis in the Sudan: clinical
features, pathology and treatment. Trans R Soc Trop
Med Hyg 1992; 86: 245–48.
12 Singh NKP, Agrawal SK, Jha TK. Visceral
leishmaniasis associated with post-kala-azar dermal
leishmaniasis. J Assoc Phys Ind 1989; 37: 191.
13 Kumar PV, Sadeghi E, Torabi S. Kala-azar with
disseminated dermal leishmaniasis. Am J Trop Med
Hyg 1989; 40: 150–53.
14 Frances C, Merle Beral H, Franceschini P, LessanaLeibowitch M, Escande JP. Kala-azar chez
l’immunodéprimé. A propos d’un cas révélé par des
signes cutanés. Presse Med 1984; 13: 2433–36.
15 Sen Gupta PC, Mukherjee AM. Lymphadenopathy
in Indian kala-azar and dermal leishmanoid. Indian J
Pathol Bacteriol 1968; 11: 172–78.
16 El-Hassan AM, El-Sheikhi EA, Eltoum IA, et al.
Post-kala-azar anterior uveitis: demonstration of
Leishmania parasites in the lesion. Trans R Soc Trop
Med Hyg 1991; 85: 471–73.
17 El Hassan AM, Khalil EAG, El Sheikh EA, et al. Postkala-azar ocular leishmaniasis. Trans R Soc Trop Med
Hyg 1998; 92: 177–79.
18 El-Hassan AM, Meredith SEO, Yagi HI, et al. Sudan
mucosal leishmaniasis: epidemiology, clinical
features, diagnosis, immune responses and
treatment. Trans R Soc Trop Med Hyg 1995; 89:
647–52.
19 Fahal AH, El Hag IA, El-Hassan AM, Hashim FA.
Leishmanial cholecystitis and colitis in a patient with
visceral leishmaniasis. Trans R Soc Trop Med Hyg
1995; 89: 284.
20 Nandy A, Addy M, Banerjee D, et al. Laryngeal
involvement during post kala-azar dermal
leishmaniaisis in India. Trop Med Int Health 1997; 2:
371–73.
21 Sen Gupta PC, Mukherjee AM. Recurrence of kalaazar associated with post- kala-azar dermal
leishmaniasis. J Indian Med Assoc 1968; 50: 1–7.
22 Nandy A, Addy M, Maji AK, et al. Recurrence of
kala-azar after PKDL: role of co-factors. Trop Med
Int Health 1998; 3: 76–78.
23 Bora D. Epidemiology of visceral leishmaniasis in
India. Nat Med J India 1999; 12: 62–68.
24 Muigai R, Gachihi GS, Oster CN, et al. Post kala-azar
dermal leishmaniasis: the Kenyan experience. East
Afr Med J 1991; 68: 801–06.
25 Rashid JR, Chunge CN, Oster CN, et al. Post-kalaazar dermal leishmaniasis occurring long after cure
of visceral leishmaniasis in Kenya. East Afr Med J
1986; 63: 365–71.
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Post-kala-azar dermal leishmaniasis
26 Munro DD. du Vivier A, Jopling WH. Post kalaazar dermal leishmaniasis. Br J Derm 1972; 87:
374–78.
27 Brahmachari UN. A new form of cutaneous
leishmaniasis-dermal leishmanoid. Indian Med Gaz
1922; 57: 125.
28 Thakur CP. Epidemiological, clinical and
therapeutic features of Bihar kala-azar (including
post kala-azar dermal leishmaniasis). Trans R Soc
Trop Med 1984; 78: 391–98.
29 Addy M, Nandy A. Ten years of kala-azar in west
Bengal, part 1. Did post kala azar dermal
leishmaniasis initiate outbreak 24-Parganas? Bull
World Health Org 1992; 70: 341–46.
30 Dinesh DS, Kar SK, Kishore K, et al. Screening
sandflies for natural infection with Leishmania
donovani, using a non-radioactive probe based on
the total DNA of the parasite. Ann Trop Med
Parasitol 2000; 94: 447–51.
31 Ashford RW, Bettini S. Ecology and epidemiology:
Old World. In: Peters W, Killick-Kendrick R, eds.
The leishmaniasis in biology and medicine.
London: Academic Press, 1987: 365–424.
32 Dye C, Wolpert DM. Earthquakes, influenza and
cycles of Indian kala-azar. Trans R Soc Trop Med
Hyg 1988; 82: 843–50.
33 Rai RN, Kumar M, Srivastava A, et al. Clinicoepidemiological profiles of post-kala-azar dermal
leishmaniasis in Varanasi. J Com Dis 1989; 21:
214–17.
34 Harith AE, Chowdhury S, Al-Masum A, et al.
Reactivity of various leishmanial antigens in a
direct agglutination test and their value in
differentiating post-kala azar dermal leishmaniasis
from leprosy and other skin conditions. J Med
Microbiol 1996; 44: 141–46.
35 Desjeux P. Information on the epidemiology and
control of the leishmaniases by country or territory.
WHO/Leish91.3 Geneva: WHO, 1991.
36 Zhong H-L, Zhang N-Z. Studies on leishmaniasis in
China. Historical background, epidemiology,
clinical aspects, legislature and control program.
Chin Med J 1986; 99: 281–300.
37 Leng Y. A review of kala-azar in China from 19491959. Trans R Soc Trop Med Hyg 1982; 76: 531–37.
38 Cross JH, Gunning J-J, Drutz DJ, Lien JC.
Introduced leishmaniasis on Taiwan. Southeast
Asian J Trop Med Pub Health 1985; 16: 381–86.
39 Cross JH, Gunning J-J, Drutz DJ, Lien JC.
Autochthonous cutaneous-subcutaneous
leishmaniasis on Taiwan. Am J Trop Med Hyg 1985;
34: 254–56.
40 Kirk R, Drew CB. Preliminary notes on dermal
leishmaniasis in the Anglo-Egyptian Sudan. Trans R
Soc Trop Med Hyg 1938; 32: 265–70.
41 Kirk R, Sati MH. Studies in leishmaniasis in the
Anglo-Egyptian Sudan. IV. A punctate rash in
treated cases. Trans R Soc Trop Med Hyg 1940; 34:
213–16.
42 El-Hassan AM, Ahmed MAM, Abdul Rahim AG, et al.
Visceral leishmaniasis in the Sudan: clinical and
hematological features. Ann Saudi Med 1990; 10:
51–56.
43 Zijlstra EE, Siddig Ali M, El-Hassan AM, et al.
Kala-azar in displaced people from southern Sudan:
epidemiological, clinical and therapeutic findings.
Trans R Soc Trop Med Hyg 1991; 85: 365–69.
44 El-Hassan AM, Ghalib HW, Zijlstra EE, et al.
Post-kala-azar dermal leishmaniasis in the absence
of active visceral leishmaniasis. Lancet 1990; 336:
750.
45 Khalil EAG, Zijlstra EE, Kager PA, El-Hassan AM.
Epidemiology and clinical manifestations of L
donovani infection in two villages in an endemic
area in eastern Sudan. Trop Med Int Health 2002; 7:
35–44.
46 El-Hassan AM, Khalil EAG. Post-kala-azar dermal
leishmaniasis: does it play a role in the transmission
of Leishmania donovani in the Sudan? Trop Med Int
Health 2001; 6: 743–44.
47 El-Hassan AM, Zijlstra EE, Meredith SEO,
Ismail A. Identification of Leishmania donovani
using a polymerase chain reaction in patient
and animal material obtained from an area of
endemic kala-azar in the Sudan. Acta Trop 1993;
55: 87–90.
48 Dereure J, Boni M, Pratlong F, et al. Visceral
leishmaniasis in Sudan: first identifications of
Leishmania from dogs. Trans R Soc Trop Med Hyg
2000; 94: 154–55.
49 Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian
visceral leishmaniasis: generic and proprietary
sodium stibogluconate are equivalent; HIV coinfected patients have a poor outcome. Trans R Soc
Trop Med Hyg 2001; 95: 668–72.
50 Manson-Bahr PEC. East African kala-azar with
special reference to the pathology, prophylaxis and
treatment. Trans R Soc Trop Med Hyg 1959; 53:
123–36.
51 Southgate BA, Oriedo BVE. Studies in the
epidemiology of East African leishmaniasis. J Trop
Med Hyg 1967; 70: 1–4.
52 Cole ACE. Kala-azar in East Africa. Trans R Soc Trop
Med Hyg 1944; 37: 409–30.
53 Baghestani S, Sodeifi M, Kumar PV. Post-kala-azar
dermal leishmaniasis. Eur J Derm 1998; 8: 277–79.
54 Alvar J, Canavate C, Gutiérrez-Solar B, et al.
Leishmania and human immunodeficiency virus
coinfection: the first 10 years. Clin Microbiol Rev
1997; 10: 298–319.
55 Alarcon Cabrera G, Garcia Garcia B,
Duaden Tello E, et al. Leishmaniasis cutanea postkala-azar en un paciente con immunodeficiencia
adquirada. Actas Dermo Sif 1987; 78: 475–77.
56 Rios-Buceta L, Buezo GF, Penas PF, et al. Post-kalaazar dermal leishmaniasis in an HIV-patient.
Int J Derm 1996; 35: 303–04.
57 Roustan G, Jiménez JA, Gutiérrez-Solar B, et al.
Post-kala-azar dermal leishmaniasis with mucosal
involvement in a kidney transplant recipient:
treatment with liposomal amphotericin B.
Br J Derm 1998; 138: 526–28.
58 Ridolfo AL, Gervasoni C, Antinori S, et al. Post-kalaazar dermal leishmaniasis during highly active
antiretroviral therapy in an AIDS patient infected
with Leishmania infantum. J Infect 2000; 40:
199–202.
59 Gilad J, Borer A, Hallel-Halevy D, et al. Post-kalaazar dermal leishmaniasis manifesting after initiation
of highly active anti-retroviral therapy in a patient
with human immunodeficiency virus infection. Isr
Med Assoc J 2001; 3: 451–52.
60 Moral L. Post-kala-azar dermal leishmaniasis and
Leishmania infantum. Br J Derm 1999; 140: 760.
61 Montelius S, Maasho K, Pratlong F, et al. Skin rash
for 15 years. Lancet 1998; 352: 1438.
62 Rodríguez-Peralto CVM, Alonso S,
Gómez-De n. -De la Fuente, Ibarrola C.
Dermatofibroma parasitized by Leishmania in HIV
infection: a new morphologic expression of dermal
kala azar in an immunodepressed patient. J Cutan
Pathol 1999; 26: 516–19.
63 Juan Martín F De, Roldán MLJ, Adana Pérez ES de,
et al. Leishmaniasis dérmica postkala-azar. Esp
Pediatr 1997; 46: 63–64.
64 González-Beato MJ, Moyano B, Sánchez C, et al.
Kaposi’s sarcoma-like lesions and other nodules as
cutaneous involvement in AIDS-related visceral
leishmaniasis. Br J Derm 2000; 143: 1316–18.
65 Hernández-Pérez J, Yebra-Bango M, JiménezMartínez E, et al. Visceral leishmaniasis (Kala-azar)
in solid organ transplantation: report of five cases
and review. Clin Infect Dis 1999; 29: 918–21.
66 Hernández DE, Oliver M, Martínez C, Planas G.
Visceral leishmaniasis with cutaneous and rectal
dissemination due to Leishmania braziliensis in
acquired immunodeficiency syndrome (AIDS). Int J
Derm 1995; 34: 114–15.
67 Barral A, Pedral-Sampaio D, Grimaldi G Jr, et al.
Leishmaniasis in Bahia, Brazil: evidence that
Leishmania amazonensis produces a wide spectrum of
clinical disease. Am J Trop Med Hyg 1991; 44: 536–46.
68 Ashford RW, Seaman J, Schorscher J, Pratlong F.
Epidemic visceral leishmaniasis in southern Sudan:
identity and systematic position of the parasites from
patients and vectors. Trans R Soc Trop Med Hyg
1992; 86: 379–80.
69 Oskam L, Pratlong F, Zijlstra EE, et al. Biochemical
and molecular characterization of Leishmania
parasites isolated from an endemic focus in eastern
Sudan. Trans R Soc Trop Med Hyg 1998; 92: 120–22.
70 Rioux JA, Lanotte G, Serres E, et al. Taxonomy of
Leishmania. Use of isoenzymes. Suggestions for a
new classification. Ann Parasitol Hum Comp 1990;
65: 111–25.
71 Pratlong F, Dereure J, Bucheton B, et al. Dedet JP.
Sudan: the possible original focus of visceral
leishmaniasis. Parasitol 2001; 122: 599–605.
72 El Tai NO, El Fari M, Mauricio I, et al. Leishmania
donovani: intraspecific polymorphisms of Sudanese
isolates revealed by PCR-based analyses and DNA
sequencing. Exp Parasitol 2001; 97: 35–44.
73 El-Masum MA, Evans DA. Characterization of
Leishmania isolated from patients with kala-azar and
post-kala-azar dermal leishmaniasis in Bangladesh.
Trans R Soc Trop Med Hyg 1995; 89: 331–32.
74 Le Blancq SM, Peters W. Leishmania in the Old
World: 4. The distribution of L donovani sensu lato
zymodemes. Trans R Soc Trop Med Hyg 1986; 80:
367–77.
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
Review
75 Chatterjee M, Manna M, Bhaduri AN, Sarkar D.
Recent kala-azar cases in India: isoenzyme profiles of
Leishmania parasites. Indian J Med Res 1995; 102:
165–72.
76 Thakur CP, Dedet JP, Narain S, Pratlong F.
Leishmania species, drug unresponsiveness and
visceral leishmaniasis in Bihar, India. Trans R Soc
Trop Med Hyg 2001; 95: 187–89.
77 Bray RS, Ashford RW, Mukherjee AM,
Sen Gupta PC. Studies on the immunology and
serology of leishmaniasis IX. Serological
investigation of the parasites of Indian kala-azar
and Indian post-kala-azar dermal leishmaniasis.
Trans R Soc Trop Med Hyg 1973; 67: 125–29.
78 Ghosh AK, Das Gupta S, Ghose AC.
Immunoglobulin G subclass-specific antileishmanial
antibody responses in Indian kala-azar and postkala-azar dermal leishmaniasis. Clin Diag Lab
Immunol 1995; 2: 291–96.
79 Das Gupta S, Ghosh DK, Majumdar HK. A cloned
kinetoplast mini-circle fragment from a Leishmania
spp. specific for post-kala-azar dermal leishmaniasis
strains. Parasitology 1991; 102: 187–91.
80 Bozza M, Fernandes O, Degrave WM, Lopes UG.
Characterization of Old World Leishmania species
using amplified minicircle variable regions as
molecular probes. Trans R Soc Trop Med Hyg 1995;
89: 333–34.
81 Haldar JP, Ghose S, Saha KC, et al. Cell-mediated
immune response in Indian kala-azar and
post-kala-azar dermal leishmaniasis. Infect Immun
1983; 42: 702–7.
82 Neogy AB, Nandy A, Ghosh Dastidar B,
Chowdhury AB. Modulation of the cell-mediated
immune response in kala-azar and post-kala-azar
dermal leishmaniasis in relation to chemotherapy.
Ann Trop Med Parasitol 1988; 82: 27–34.
83 Kemp M, Theander TG, Kharazmi A. The
contrasting roles of CD4+ cells in intracellular
infections in human: Leishmania as an example.
Immunol Today 1996; 17: 13–17.
84 Ismail A, Hassan ELAM, Kemp K, et al.
Immunopathology of post kala-azar dermal
leishmaniasis (PKDL): T-cell phenotypes and
cytokine profile. J Pathol 1999; 189: 615–22.
85 Gasim S, Elhassan AM, Khalil EAG, et al. High levels
of plasma IL-10 and expression of IL-10 by
keratinocytes during visceral leishmaniasis predict
subsequent development of post-kala-azar dermal
leishmaniasis. Clin Exp Immunol 1998; 111: 64–69.
86 Ghosh MK, Nandy A, Addy M, Maitra TK,
Ghose AC. Subpopulations of T lymphocytes in the
peripheral blood, dermal lesions and lymph nodes
of post-kala-azar dermal leishmaniasis patients.
Scand J Immunol 1995; 41: 11–17.
87 Zijlstra EE, El-Hassan AM. Leishmanin and
tuberculin sensitivity in leishmaniasis in the Sudan,
with special reference to kala-azar. Trans R Soc Trop
Med Hyg 1993; 87: 425–27.
88 Ismail A. Immune responses and immunopathology
of post kala-azar dermal leishmaniasis (PKDL) (PhD
thesis). Copenhagen: University of Copenhagen;
1999.
89 El-Hassan AM, Ali MS, Zijlstra EE, et al. Post kalaazar dermal leishmaniasis in the sudan: peripheral
neural involvement. Int J Derm 1992; 31: 400–3.
90 Ismael A, Kharazmi A, Permin H, El-Hassan AM.
Detection and characterization of Leishmania in
tissues of patients with post kala-azar dermal
leishmaniasis using a specific monoclononal
antibody. Trans R Soc Trop Med Hyg 1997; 91:
283–85.
91 Ramesh V, Misra RS, Saxena U, Mukherjee A. Postkala-azar dermal leishmaniasis: a clinical and
therapeutical study. Int J Derm 1993; 32: 272–75.
92 Mukherjee A, Ramesh V, Misra RS. Post-kala-azar
dermal leishmaniasis: a light and electron
microscopic study of 18 cases. J Cutan Pathol 1993;
20: 320–25.
93 Khalil EAG, Hashim FA, Ghalib HW, et al.
Comparative study of liposomal amphotericine B
(AmBisome) and sodium stibogluconate in the
treatment of kala-azar in the Sudan. East Afr Med J
1998; 75: 481–84.
94 Osman OF, Oskam L, Zijlstra EE, et al. Use of the
polymerase chain reaction to assess the success of
visceral leishmaniasis treatment. Trans R Soc Trop
Med Hyg 1998; 92: 397–400.
95 Gasim S, Theander TG, Elhassan AM. High levels of
C-reactive protein in the peripheral blood during
visceral leishmaniasis predict subsequent
development of post kala-azar dermal leishmaniasis.
Acta Trop 2000; 75: 35–38.
96 Sharma MC, Gupta AK, Verma N, et al.
Demonstration of Leishmania parasites in skin
lesions of Indian post kala-azar dermal leishmaniasis
97
For personal use. Only reproduce with permission from The Lancet Publishing Group.
Review
(PKDL) cases. J Commun Dis 2000; 32: 67–8.
97 Meredith SEO, Zijlstra EE, Schoone GJ, et al.
Development and application of the polymerase
chain reaction for the detection and identification of
Leishmania parasites in clinical material. Arch Inst
Pasteur Tunis 1993; 70: 419–31.
98 Osman OF, Oskam L, Kroon NCM, et al. Use of
PCR for diagnosis of post-kala-azar dermal
leishmaniasis. J Clin Microbiol 1998; 36: 1621–24.
99 Salotra P, Sreenivas G, Pogue GP, et al. Development
of a species-specific PCR assay for detection of
Leishmania donovani in clinical samples from
patients with kala-azar and post-kala-azar dermal
leishmaniasis. J Clin Microbiol 2001; 39: 849–54.
100 Singh S, Kumari V, Singh N. Predicting kala-azar
disease manifestations in asymptomatic patients
with latent Leishmania donovani infection by
detection of antibody against recombinant K39
antigen. Clin Diag Lab Immunol 2002; 9: 568–72.
101 Harith AE, Chowdhury S, Al-Masum A, et al.
Reactivity of various leishmanial antigens in a direct
agglutination test and their value in differentiating
post-kala azar dermal leishmaniasis from leprosy
and other skin conditions. J Med Microbiol 1996; 44:
141–46.
102 Zijlstra EE, Nur Y, Desjeux P, et al. Diagnosing
visceral leishmaniasis with the recombinant k39 strip
test: experience from the Sudan. Trop Med Int
Health 2001; 6: 108–13.
103 Kual P, Malla N, Kaur S, Mahajan RC,
Ganguly NK. Evaluation of a 200-kDa amastigote
antigen of L. donovani by enzyme-linked
immunosorbent assy (ELISA) for the diagnosis of
visceral leishmaniasis. Trans R Soc Trop Med Hyg
2000; 94: 173–75.
104 Salotra P, Raina A, Ramesh V. Western blot analysis
of humoral immune response to Leishmania
donovani antigens in patients with post-kala-azar
dermal leishmaniasis. Trans R Soc Trop Med Hyg
1999; 93: 98–101.
98
Post-kala-azar dermal leishmaniasis
105 Chatterjee M, Jaffe CL, Sundar S, et al. Diagnostic
and prognostic potential of a competitive enzymelinked immunosorbent assy for leishmaniasis in
India. Clin Diag Lab Immunol 1999; 6: 550–54.
106 Salotra P, Sreenivas G, Ramesh V, Sundar S. A
simple and sensitive test for field diagnosis of post
kala-azar dermal leishmaniasis. Br J Derm 2001; 145:
630–32.
107 Neogy AB, Nandy A, Chowdhury AB. Leishmanin
test in post-kala-azar dermal leishmaniasis. Trans R
Soc Trop Med Hyg 1990; 84: 58.
108 El-Hassan AM, Hashim FA, Abdalla M, Zijlstra EE,
Ghalib HW. Distinguishing post-kala-azar dermal
leishmaniasis from leprosy: experience in the Sudan.
Lepr Rev 1993; 64: 53–59.
109 Lal S, Garg BR. Post-kala-azar dermal leishmaniasis
simulating leprosy. Lepr India 1976; 48: 81–83.
110 Muir E. The differential diagnosis of leprosy and
dermal leishmaniasis. Indian Med Gaz 1930; 65:
257–58.
111 Ramesh V, Saxena UM, Misra RS, Mukherjee A.
Post-kala-azar dermal leishmaniasis: a case report
strikingly resembling lepromatous leprosy. Lepr Rev
1991; 62: 217–21.
112 Ramesh V. On the differences between post-kalaazar dermal leishmaniasis and leprosy. Trop Doct
1994; 24: 120–1.
113 Yesuian P, Thambiah AS. Amphotericin B therapy
in dermal leishmanoid. Arch Derm 1974; 109: 720–22.
114 Saha SK. Dermal leishmaniasis after kala-azar
infection: successful treatment with rifampin. n:
Cutis 1985; 36: 81–82.
115 Thakur CP, Kumar K, Sinha PK, Mishra BN,
Pandey AK. Treatment of post-kala-azar dermal
leishmaniasis with sodium stibogluconate. BMJ
1987; 295: 886–7.
116 Ramesh V, Saxena U, Misra RS. Efficacy of
ketoconazole in post-kala-azar dermal leishmaniasis.
Arch Derm 1992; 128: 411–12.
117 Khalil EAG, Nur NM, Zijlstra EE, El-Hassan AM,
Davidson RN. Failure of a combination of two
antifungal drugs, terbinafine and itraconazole, in
Sudanese post kala-azar dermal leishmaniasis. Trans
R Soc Trop Med Hyg 1996; 90: 187–88.
118 Ramesh V. Allopurinol therapy in post-kala-azar
dermal leishmaniasis. Acta Derm Venereol 1996; 76:
328–29.
119 Hashim FA, Khalil EAG, Ismael A, El-Hassan AM.
Apparently successful treatment of two cases of post
kala-azar dermal leishmaniasis with liposomal
amphotericine B. Trans R Soc Trop Med Hyg 1995;
89: 440.
120 Thakur CP, Narain S, Kumar N, et al. Amphotericin
B is superior to sodium antimony gluconate in the
treatment of Indian post-kala-azar dermal
leishmaniasis. Ann Trop Med Parasitol 1997; 91:
611–6.
121 Ramesh V, Misra RS, Khunger N, et al. Shave
excision as an adjunct to the therapy of a
rhinophyma-like complication in post-kala-azar
dermal leishmaniasis. Acta Derm Venereol 1999; 79:
330–31.
122 Mishra M, Biswas UK, Jha DN, Khan AB.
Amphotericin versus pentamidine in
antimony-unresponsive kala-azar. Lancet 1991; 337:
926.
123 Sundar S, Rosenkaimer F, Makharia MK, et al. Trial
of oral miltefosine for visceral leishmaniasis. Lancet
1998; 352: 1821–23.
124 Murray HW. Treatment of visceral leishmaniasis
(Kala-azar): A decade of progress and future
approaches. Int J Infect Dis 2000; 4: 158–77.
125 Schmidt-Ott R, Klenner T, Overath P,
Aebischer T. Topical treatment with
R
hexadecylphosphocholine (Miltex ) efficiently
reduces parasite burden in experimental cutaneous
leishmaniasis. Trans R Soc Trop Med Hyg 1999; 93:
85–90.
THE LANCET Infectious Diseases Vol 3 February 2003
http://infection.thelancet.com
For personal use. Only reproduce with permission from The Lancet Publishing Group.